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Abstract
Background: Obesity paradox is defined as the unexpected decrease in the total number of death which has been
observed among patients who are overweight and obese compared to patients with normal weight after undergoing
revascularization by percutaneous coronary intervention (PCI). Despite of so many recent studies which showed the
existence of this phenomenon, prolonged and intensive medication use were only suggested to be among the
reasons responsible for this ‘obesity paradox’ but it was never confirmed whether this hypothesis should really be
considered true or not. Therefore, this study aimed to investigate whether prolonged and intensive medication use
were associated with this obesity paradox after PCI.
Methods: Medline, PubMed, EMBASE and the Cochrane Library were searched for studies showing the existence of
this ‘obesity paradox’ in patients who underwent coronary revascularization by PCI and only articles comprising of
medication use among the patients analyzed were considered relevant for this research. Medication use among the
different subgroups of patients was calculated. Mortality was considered as the clinical endpoint in this study. Risk Ratio
(RR) with 95 % Confidence Interval (CI) was used to express the pooled effect on discontinuous variables and the
pooled analyses were performed with RevMan 5.3.
Results: Twelve studies consisting of a total number of 91,582 patients was included in this meta-analysis. An
intensive medication use after the hospital discharge and during the follow up period after PCI was observed in
the subgroup of obese patients, followed by the overweight patients and the normal weight patients respectively. Our
results showed that the short-term (30 days) mortality in overweight and obese patients was significantly lower
compared to the normal weight patients with RR: 0.72; 95 % CI: 0.56-0.92, p = 0.008 and RR: 0.47, 95 % CI: 0.34-0.65;
p < 0.00001 respectively. The long-term (≥ one year) mortality was also significantly lower in the overweight and the
obese groups with RR: 0.74, 95 % CI: 0.67-0.82; p < 0.00001 and RR: 0.63, 95 % CI: 0.55-0.72; p < 0.00001 respectively.
Conclusion: Our study has confirmed to some extent, that prolonged and intensive use of medications which were
more prominent in patients who were overweight and obese during the follow up period, might apparently be
among the reasons responsible for this obesity paradox after PCI.
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Background
Obesity paradox is referred to as the unexpected decrease
in the total number of deaths observed among patients
who are overweight and obese, compared to normal
weight patients after undergoing revascularization by
percutaneous coronary intervention (PCI) [1–3]. In con-
trast to patients with normal weight, because overweight
and obese patients are candidates with high risk for
cardiovascular diseases, and most probably suffer from
co-morbidities such as hypertension, dyslipidemia, meta-
bolic syndrome and diabetes mellitus at an early age,
prolonged and intensive medical treatment including
anti-hypertensive drugs such as diuretics and angiotensin
converting enzyme inhibitors (ACEI), lipid-lowering agents
such as statin, oral anti-hyperglycemic agents and anti-
platelet medications such as aspirin to prevent and treat
their underlying clinical conditions, eventually combined
with daily exercises, change in diet, and intentional weight
loss included in their treatment regimens are strictly
considered at an early age.
Studies have shown that even though these patients
have a high risk profile at the time of PCI, the use of
multiple cardiovascular medications was associated with
favorable clinical outcomes [4]. Certain studies have men-
tioned that the difference in optimal use of medications
at follow-up among the subgroups with a high body
mass index (BMI) when compared to patients with nor-
mal weight, has also partly contributed to this obesity
paradox [5–7].
Despite of so many recent studies which showed the
existence of this phenomenon, prolonged and intensive
medication use were only suggested to be among the
reasons which were responsible for this ‘obesity paradox’
but it was never confirmed whether this hypothesis should
really be considered true or not [8]. Therefore, this study
aimed to investigate whether prolonged and intensive




Studies showing the existence of this ‘obesity paradox’ in
patients who underwent coronary revascularization by
PCI were searched through Medline, PubMed, EMBASE
and the Cochrane Library by typing the words and
phrases ‘obesity paradox and percutaneous coronary
intervention’, and ‘obese and mortality and percutaneous
coronary intervention’. To further enhance this search,
the term ‘overweight and obese’ which was interchange-
able with the term ‘high BMI’ was also used. Moreover,
the abbreviation ‘PCI’ was used and it was also replaced
by the word ‘coronary angioplasty’. Only studies published
in English were considered in this search process. Table 1
shows the number of citations obtained during the search
of studies by using appropriate keywords.
Inclusion and exclusion criteria
Studies were included if:
(a)They were randomized controlled trials (RCTs) or
observational studies comparing normal weight,
overweight and obese patients after revascularization
with PCI.
(b)They reported mortality as their clinical endpoints.
(c)They also included the medications prescribed at
discharge or during the follow-up period after PCI.
This feature was a major part in assessing studies
which were eligible for this research.
Studies were excluded if:
(a)They were neither RCTs nor observational studies
(they were meta-analyses and case studies).
(b)They did not compare overweight and obese
patients with normal weight patients after PCI.
(c)Mortality was not reported among their clinical end
points.
(d)Medication use or prescription at discharge or
follow up was not mentioned (studies were not
included if mortality was among the endpoints but
medication prescribed at discharge or follow-up was
not mentioned).
(e)Only their abstracts were made available.
(f )Data for the control group (normal weight patients)
were not available.
Outcomes and follow up
In hospital, short-term (30 days to one year) and long-term
mortality (≥1 year) were considered as the only outcome
for this study.
Definitions
Normal weight patients: were defined as patients with
a BMI > 18.5 but <25 kg/m2.
Table 1 Number of articles obtained during the search process




obesity paradox and percutaneous coronary
intervention
1098
obese and mortality and percutaneous coronary
intervention
1312
overweight and obese/high BMI and PCI 345
Obesity paradox and PCI 809
Total no of articles obtained (n) 3564
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Overweight patients: were defined as patients with a
BMI > 25 kg/m2 but <30 kg/m2.
Obese patients: were defined as patients with a BMI
> 30 kg/m2.
High BMI patients: including both overweight and
obese patients, were defined as patients with a BMI
> 25 kg/m2.
Exceptions were also present in this study. Among all
the studies included, one study assumed normal weight
patients to have a BMI > 18.5 to <23 kg/m2 whereas an-
other study assumed normal weight patients to have a
BMI of 18.5- <24 kg/m2 instead of the standard BMI
range of 18.5 to 25 kg/m2. In this same study, BMI of
23–27.5 kg/m2 and >27.5 kg/m2 were considered for over-
weight and obese patients respectively. Another study
assumed a BMI of 24-27 kg/m2 and >27 kg/m2 to be
overweight and obese respectively.
Medication use: included multiple cardiovascular med-
ications such as beta-blockers, angiotensin converting en-
zyme inhibitors (ACEI) or angiotensin receptor blockers
(ARB), lipid-lowering medications (statins), diuretics and
antiplatelet drugs such as aspirin and clopidogrel used
earlier before PCI, or prescribed at discharge or during
the follow-up period to be used continuously in order to
prevent complications.
Prolonged medication use: defined as the use of
these cardiovascular medications since the beginning of
previously diagnosed conditions such as hypertension or
hypercholesterolemia/hyperlipidemia in these high risk
profile patients, which could be earlier before PCI or
during the follow-up period after PCI. For example, beta
blockers used to treat hypertension and statin used earl-
ier for the prevention or treatment of hyperlipidemia in
these overweight and obese patients, and later these
drugs were continued to be used together along with
additional medications for example clopidogrel use for
one year and lifelong aspirin post PCI or the continuous
use of statin during the follow up period.
Intensive medication use and treatment: We believe
that both the mg/kg and the one-size-fits-all strategy for
prescribing medications are outdated as individual body
size and composition characteristics of patients are likely
to clinically significantly affect pharmacokinetic parame-
ters. Further adjusting the dosage could improve efficacy
in these high BMI patients. Hence, a higher drug dosage
use calculated according to the body weight will vary de-
pending on the size/weight of the individual. Total body
weight, ideal or adjusted body weights are used for these
high BMI patients. Use of medications for the preven-
tion of unwanted conditions beforehand such as statin
use even if the patient does not have hyperlipidemia yet
but is at high risk for this condition, frequent home
glucose monitoring in those suffering from diabetes,
continuous visit to the physician for medical check-ups
and counseling including lifestyle counseling, weight man-
agement and other health tips were all considered in this
intensive treatment plan.
Mortality: was defined as death of all causes including
cardiac and non-cardiac deaths.
In-hospital mortality: was defined as death occurring
during the hospital stay just after PCI but before being
discharged from the hospital.
Short-term mortality: was defined as death occurring
after hospital discharge and during a follow up period
of one year after PCI. This short-term follow up period
was divided into a follow up period of 30 days and a
follow up period during one year. Follow up period at
one year has been classified in the long-term category.
Long-term mortality: was defined as death occurring at
one year or after one year (≥1 year).
Data extraction process
The authors X.F.T. and J.X.S. independently reviewed all
the studies and assessed them for eligibility. Several in-
formation was extracted including the characteristics/
features of the patients involved, the total number of
normal weight, overweight and obese patients, the medi-
cation used in each subgroup of patients, the mortality
reported as well as the follow up periods. Selected stud-
ies were carefully checked and filtered for the inclusion
of medication use at discharge or during the follow-up
period. Any disagreement raised during this data extraction
process has been carefully discussed between these two au-
thors, and if they could not reach a decision, M.H.C., the
third author was called to discuss and resolved the
problem. Assessment of the bias risks within the studies
with the components recommended by the Cochrane
Collaboration [9] was not conducted since all the stud-
ies were observational cohorts.
Statistical analysis
A bar chart has been used to represent the percentage of
patients using specific medications among the different
BMI subgroups and Risk Ratio (RR) with 95 % confidence
interval (CI) was used to express the pooled effect on
discontinuous variables related to post-PCI mortality.
Heterogeneity across trials was assessed using the
Cochrane Q-statistic (p 0 · 05 was considered significant
whereas p > 0.05 was considered statistically insignificant)
and the I2-statistic which described the percentage of total
variation across studies; that is, due to heterogeneity ra-
ther than chance (whereby an I2 with low percentage
represented a lower heterogeneity whereas an increasing
percentage denoted an increasing heterogeneity). If I2 was
less than 50 %, a fixed effect model was used. However, if
I2 was more than 50 %, a random effect model was used.
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Publication bias was visually estimated by assessing funnel
plots. We calculated RR and 95 % CIs for categorical vari-
ables. The pooled analyses were performed with RevMan
5.3 software.
Results
The preferred reporting items for systematic reviews and
meta-analyses (PRISMA) guideline was followed in this
study. During our search for eligible studies, based upon
titles and abstracts, 3,564 articles were obtained from the
above mentioned electronic databases. 3,504 publications
have been eliminated on the basis of title and abstract
because they were not related to our topic or they were
duplicates. 60 full-text articles were assessed for eligibility.
Further articles were excluded since they were: meta-
analyses or case studies, data for the control group were
not available, and data concerning medications prescribed
at discharge or during the follow up period were not
reported. Finally, 12 studies with a total number of
91,582 patients satisfied all the inclusion criteria and
were confirmed for this meta-analysis. The flow diagram
for identifying potentially eligible studies and the reasons
for inclusion and exclusion have been represented in
Fig. 1.
The baseline characteristics of the studies included in
this meta-analysis have been listed in Table 2.
According to the baseline features, the study published
by Das et al. [10] involved the majority of patients in all
the different subgroups of patients (11,780 patients who
had a normal weight, 19,391 patients who were overweight
and 18,158 patients who were obese). Obese patients were
younger than patients with normal weight and male pa-
tients were higher in all the BMI subgroups compared to
female patients. The study by Akin et al. [12] had the high-
est number of obese patients with hypertension. Moreover,
the study by Kang et al. [11] had the highest number of
patients who were current smokers. Most of the patients
who were obese also had diabetes mellitus.
The medications prescribed at discharge and during
the follow up period have been represented in Table 3.
According to Table 2, 94.7 % of patients with normal
weight, 95.1 % of the patients who were overweight and
95.0 % of the patients who were obese used aspirin.
82.4 %, 83.1 % and 83.2 % of the patients with normal
weight, overweight and obese respectively used clopido-
grel. Normal weight, overweight and obese patients using
beta blocker and statin were 70.4 % and 76.8 %, 72.1 %
and 79.3, and 73.8 % and 93.3 % respectively. Medication
use was higher among patients who were overweight and
highest among patients who were obese. Overweight
patients used more medications than normal weight pa-
tients whereas obese patients used more medications
Fig. 1 Flow diagram for the study selection
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than overweight patients after PCI. A flow chart show-
ing the percentage of medication use by the different
subgroups of patients has been illustrated in Fig. 2.
The percentage of in-hospital death among the differ-
ent subgroups of patients after PCI has been represented
in Table 4. In-hospital death was lower in the overweight
and obese patients compared to the normal weight pa-
tients with the exception of patients from the study
Numasawa et al.[16].
Short and long-term deaths in patients with normal
weight, overweight and obese after PCI have been repre-
sented in Tables 5 and 6 respectively. Short and long-term
deaths were lower among patients who were overweight
and obese compared to those with normal weight with
the exception of patients from the study published
Wang et al.[15].
Results of the meta-analysis
In hospital mortality
In-hospital mortality among overweight and obese patients
were significantly lower compared to the normal weight pa-
tients with RR: 0.64, 95 % CI: 0.59-0.70; p < 0.00001 for pa-
tients who were overweight and with RR: 0.61, 95 % CI:
0.41-0.89; p = 0.01 for patients who were obese. These
results have been shown in Figs. 3 and 4 respectively.
Short term mortality
Short term mortality was classified into two parts. One
part compared the mortality during a 30-days period
while the other part compared the mortality during a
follow up period from 30 days to one year.
During the 30 days follow up, mortality was signifi-
cantly lower in the overweight and obese groups with
RR: 0.72, 95 % CI: 0.56–0.92; p = 0.008 and RR: 0.47,
95 % CI: 0.34–0.65; p < 0.00001 respectively.
When a follow up from 30 days to one year was consid-
ered, mortality was still significantly lower in the obese
group with RR: 0.51, 95 % CI: 0.33–0.78; p = 0.002. Results
for the short term follow up have been illustrated in Fig. 5.
Long-term mortality
Long-term mortality was also significantly lower in the
overweight and obese patients with RR: 0.74, 95 % CI:
0.67-0.82; p < 0.00001 and RR: 0.63, 95 % CI: 0.55–0.72;
p < 0.00001 respectively. The result for the long-term
follow up has been represented in Fig. 6.
For all of the above analyses, sensitivity analyses yielded
consistent results. Based on a visual inspection of the fun-
nel plot, there has only been little evidence of publication
bias for the included studies that assessed mortality during
different follow up periods. The funnel plot has been
illustrated in Fig. 7.
Discussion
Several hypotheses have previously been suggested for
this obesity paradox. It was suggested in many studies
that the prolonged and intensive use of medications in
overweight and obese patients could be among the
Table 2 shows the baseline characteristics of the included studies
Study Patients (n) Age (yrs) Men (%) HT (%) Ds (%) CS (%) DM (%)
N/Ov/Ob N/Ov/Ob N/Ov/Ob N/Ov/Ob N/Ov/Ob N/Ov/Ob N/Ov/Ob
Das2011 [10] 11780/19391/18158 66.0/60.0/56.3 61.9/75.3/69.6 56.9/58.5/69.3 43.4/49.7/55.4 45.0/43.1/42.1 14.8/19.5/35.3
Kang 2010 [11] 1253/1959/483 64.7/59.4/56.5 70.9/79.5/76.4 39.9/47.2/54.2 7.0/10.4/12.7 60.3/64.2/66.2 22.5/23.5/28.7
Lancefield 2010 [8] 1189/2016/1426 67.4/64.7/61.4 73.2/79.0/68.8 58.6/61.9/74.1 68.5/71.7/75.6 23.4/19.9/23.2 15.9/22.3/33.6
Akin 2012 [12] 1436/2839/1531 66.1/65.5/63.7 69.8/78.5/72.1 75.4/84.2/91.2 75.9/81.0/83.5 26.3/21.4/20.4 21.5/29.2/46.9
Cheng 2013 [13] 477/428/340 67.7/61.9/57.9 80.1/84.3/85.0 53.5/55.8/56.2 NM 44.0/40.4/36.5 36.7/36.4/32.9
He 2015 [14] 489/447/81 NM 67.7/68.0/58.0 62.8/76.3/72.8 48.7/51.0/50.6 16.4/13.6/14.8 27.4/26.4/24.7
Wang 2012 [15] 1592/3026/1465 60.9/58.8/56.8 62.7/64.7/66.4 58.0/60.8/70.9 30.3/30.9/38.1 44.4/42.4/40.2 34.6/33.5/38.4
Numasawa 2015 [16] 5945/3100/635 69.4/65.4/59.2 79.3/83.5/78.7 70.9/80.0/84.9 63.9/72.9/78.4 33.3/38.7/44.7 40.0/46.4/58.6
Buettner 2007 [17] 551/824/292 65.9/64.7/62.7 67.0/75.0/61.0 55.0/62.0/70.0 60.0/68.0/69.0 21.0/25.0/24.0 17.0/18.0/25.0
Kaneko2013 [18] 640/417/56 66.8/63.2/55.2 81.4/87.8/92.9 61.3/71.7/69.6 56.6/66.7/71.4 33.4/41.7/62.5 33.4/35.7/48.2
Schenkeveld 2012 [5] 2095/2956/1246 62.0/62.0/59.0 70.0/77.0/67.0 34.0/39.0/55.0 73.0/76.0/79.0 27.0/22.0/23.0 12.0/16.0/27.0
Younge2013 [19] 354/468/197 63.0/63.0/60.0 70.0/76.0/68.0 32.0/28.0/25.0 56.0/59.0/61.0 35.0/42.0/54.0 10.0/16.0/24.0
Abbreviations: N normal weight, Ov overweight, Ob obese, NM not mentioned, HT hypertension, Ds dyslipidemia, CS current smoker, DM diabetes mellitus, yrs years
Table 3 shows the medications at discharge and during follow-up









Aspirin (%) 94.7 95.1 95.0
Clopidogrel (%) 82.4 83.1 83.2
Statin (%) 76.8 79.3 81.3
ACEI/ARBs (%) 55.8 65.2 68.8
Beta blocker (%) 70.4 72.1 73.8
Abbreviations: ACEI angiotensin converting enzyme inhibitor, ARB angiotensin
receptor blocker
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reasons responsible for this phenomenon [5, 8]. Over-
weight and obese patients are more exposed to cardio-
vascular risk factors and because majority of these
patients suffer from conditions like hypertension, dys-
lipidemia and diabetes mellitus, they are first treated
for these conditions since an early age [20, 21]. Increased
use of medications such as beta blockers, statins and
ACEI/ARB, with increased dosage, along with additional
medications such as antiplatelet agents (aspirin and clopi-
dogrel) prescribed after PCI seem to have all contributed
to this paradox.
Our results showed that medication use was more
intense among patients who were obese followed by
patients who were overweight. Moreover, our results
showed that since cardiac medications were intensively
used among these high risk patients, these medications
could be associated with this significant decrease in in-
hospital, short term as well as the long-term mortality
when compared to patients with normal weight who
did not use intensive medications.
In our study, we tried to investigate the impact of
prolonged and intensive medication use on the obesity
paradox and our results could partly show the association
of intensive medication use with this phenomenon. How-
ever, even in other studies, it was suggested that intensive
medication use among patients with high BMI was as-
sociated with a lower mortality risk. Lancefield et al.
concluded that patients who were obese had a higher
rate of guideline-based medication use at 12 months,
which might in part explain the obesity paradox seen after
PCI [8]. Steinberg et al. also found that increased BMI was
related to an increased use of guideline-based medical
therapy both in-hospital and at discharge in 130,139 pa-
tients hospitalized for coronary artery disease [22].
Moreover, in the study published by Kennedy et al., the
authors found that BMI was associated with an increased
mortality risk among obese patients who were not re-
ceiving beta-blocker or renin angiotensin system-blockade
(RAS) [23]. However, non-pharmacological measures such
as smoking cessation, cardiac rehabilitation, and dietary
counseling have also shown to be more prominent and
visible in patients who were overweight and obese
altogether contributing to this obesity paradox [24].
Schenkeveld et al. also supported the fact that patients
with high BMI were given priority on optimal medical
treatment, which could in a certain way explain the de-
crease in mortality rate after PCI thus contributing to this
obesity paradox [5]. Their study found that this inverse re-
lationship between high BMI and mortality rate persisted
Fig. 2 Medications at discharge and during the follow-up period
Table 4 shows the Percentage of In-hospital Death among the
different subgroups of patients
Normal weight Overweight Obese
(%) (%) (%)
Das 2011 7.4 4.7 4.4
Kang 2010 4.4 3.0 1.7
Lancefield 2010 1.2 0.9 0.5
Akin 2012 0.8 0.5 0.3
He 2015 1.0 0.4 0.0
Numasawa 2015 2.1 1.2 2.7
Table 5 shows the Percentage of Short-term Death among the
different subgroups of patients
30 days follow up Normal weight Overweight Obese
(%) (%) (%)
Buettener 2007 2.0 2.3 1.0
Lancefield 2010 1.6 1.1 1.05
Kang 2010 1.2 1.0 0.2
Cheng 2013 19.3 12.1 8.5
30 days to 1 year follow up
Kang 2010 2.0 1.6 0.9
Lancefield 2010 4.0 2.9 2.1
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even during the long-term follow-up after PCI. Patients
from the overweight and obese groups showed almost
30 % lower mortality rate compared to patients with a
normal BMI. In their cohort study, patients with a high
BMI were often prescribed beta blocker and ACEI
enormously when compared with normal weight patients
indirectly explaining this obesity paradox.
In addition, the study published by Claudio et al.
found that thirty-day readmissions related to ‘acute cor-
onary syndrome (ACS)/heart failure’ admission diagnosis
were rare among patients with high BMI. But only those
patients with ‘ACS/heart failure’ who had periprocedural
myocardial infarction as the only independent predictor
showed a detrimental impact on prognosis [25]. In their
study, periprocedural myocardial infarctions was a marker
for a higher risk of atherothrombotic events and their
detrimental effect on ejection fraction, potentially lead-
ing to hemodynamic instability. During the early period
of discharge, these patients were closely monitored and
medications were administered to their maximal tolerated
dosage. This result was consistent with our study in which
showed intensive use of medications during the follow up
period might be among the reasons responsible for a
lower mortality risk among patients with high BMI thus
contributing to this obesity paradox. However, not only
prolonged and intensive medication use could be associ-
ated with this phenomenon. The beneficial effect of inten-
sive medical therapy among patients with high BMI might
also have been influenced by a change in lifestyle. Other
factors such as healthy dieting, regular exercises, quitting
smoking and referral to cardiac rehabilitation as men-
tioned above could also have contributed to this beneficial
long-term prognosis in these patients [5]. In addition, as
shown in the baseline features of this study, a younger
age among patients with high BMI could also be a factor
contributing to this ‘obesity paradox’. Certain studies have
also suggested larger coronary arteries among patients
who are overweight and obese could also be associated to
this lower mortality risk after PCI as mentioned in the
study by Bundhun et al. [26]. Prolonged and intensive
medication use might not be the only factor contributing
to this obesity paradox after PCI.
This study is new in the way that it is among the first
study investigating whether prolonged and intensive
medication use are associated with the obesity paradox
after PCI. Several studies have shown the existence of
this phenomenon but none has previously investigated
its association with the use of aggressive medications.
Limitation
This study also has limitations. First of all, extremely
obese patients were also included in the category of
obese patients. This could possibly have an effect on the
result since obesity could further be divided into several
classes. Secondly, one or two studies included in our
meta-analysis assumed normal weight patients to have a
BMI > 20 but <25 kg/m2 whereas other studies classified
overweight patients to have a BMI ranging from 24 kg/m2
to <27 kg/m2 while obese patients had a BMI of >27 kg/m2
instead of >30 kg/m2. This could have an effect on our
results. In addition, our study did not consider some
factors which such as the clinical presentation (acute
coronary syndrome vs stable angina) and procedural
Table 6 shows the Percentage of Long-term (≥ one year)
Death among the different subgroups of patients
Normal weight Overweight Obese
(%) (%) (%)
Kang 2010 3.3 2.6 1.1
Buettner 2007 7.4 5.1 2.7
Akin 2012 3.3 2.4 2.4
Younge 2013 7.1 6.3 3.0
Wang 2012 2.4 2.3 2.7
He 2015 1.8 1.8 0.0
Kaneko 2013 4.8 2.2 3.6
Schenkeveld 2012 21.2 15.0 13.0
Fig. 3 In-hospital mortality among overweight patients after PCI
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features including lesion type, number of implanted stents,
type of the stents which could all have an influence on the
prognosis of patients after PCI. Another limitation for this
study might be considered to the fact that the in-hospital
follow up was too short for the medications to be effective.
So, the intensive use of medications should be highly asso-
ciated with the long-term mortality risk in these patients
after PCI.
Conclusion
Our study has confirmed to some extent, that prolonged
and intensive use of medications which were more prom-
inent in patients who were overweight and obese during
the follow up period, might apparently be among the
reasons responsible for this obesity paradox after PCI.
Further investigations are required to completely solve
this issue.
Fig. 4 In-hospital mortality among obese patients after PCI
Fig. 5 Short-term mortality after PCI
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Fig. 6 Long-term mortality after PCI
Fig. 7 Funnel plot for the sensitivity analysis
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ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
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